Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C20H23N7O6 |
| Molecular Weight | 457.4399 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(N3CN(CC3CN2)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C(=O)N1
InChI
InChIKey=QYNUQALWYRSVHF-ABLWVSNPSA-N
InChI=1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12?,13-/m0/s1
Folitixorin, a thymidylate synthase inhibitor is a substrate used by the enzyme methylenetetrahydrofolate reductase (MTHFR) to generate 5-methyltetrahydrofolate. Folitixorin was studied in clinical trials for the treatment of breast cancer, metastatic colorectal cancer and for the treatment of advanced pancreatic cancer. Folitixorin had been granted orphan drug status for the treatment of pancreatic cancer in both the U.S. and EU. However, further development of this drug was discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. | 1995 May |
|
| Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? | 2006 Jun |
|
| Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism. | 2008 Jan |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2078
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5,10-Methylenetetrahydrofolate
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
0SXY5ET48B
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
C61304
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL117348
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
100000181840
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
8881
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
DTXSID90955873
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
3432-99-3
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
C013123
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
1989
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
135400185
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | |||
|
EU/3/03/143(WITHDRAWN)
Created by
admin on Fri Dec 15 16:05:14 GMT 2023 , Edited by admin on Fri Dec 15 16:05:14 GMT 2023
|
PRIMARY | Treatment pancreatic cancer in combination with 5-fluorouracil 11/6/2003 Withdrawn |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
